Moreover, immunohistochemical evaluation of the downstream target of mTOR, phosphorylated S6 ribosomal protein (p-S6RP), has been correlated with an early clinical response to mTOR inhibitors (AP23573) administered either alone or in combination to a cohort of patients with varying types of sarcomas [13]. The gene discussed is MTOR; the disease is sarcoma.